Rhythm Pharmaceuticals, Inc. (RYTM) Discusses FDA Approval of IMCIVREE for Acquired Hypothalamic Obesity Transcript

Group 1 - The conference call is hosted by Rhythm Pharmaceuticals, indicating a focus on investor relations and communication with stakeholders [1] - David Connolly is the first speaker, suggesting a structured approach to the presentation with designated roles [1]